HPV is a sexually transmitted infection and the primary cause of genital warts and anogenital cancers. A new prophylactic HPV vaccine is recommended for routine use in females ages 11-12 years with catch-up for 13-26 year olds. Evaluating the impact of the vaccine requires monitoring several biologic and behavioral endpoints.

Objectives of Symposium:

Provide an overview of national efforts to develop sustainable systems to monitor the impact of HPV vaccine on disease outcomes and screening behaviors.

Implications for Programs, Policy, and/or Research:

Information presented will highlight national efforts toward a coordinated approach to HPV impact monitoring and the role of STD programs therein.